[The role of ofloxacin (Tarivid) therapy in respiratory and urinary tract infections].
In this study, 14 patients with urinary tract infection and 8 patients with respiratory tract infection were given 400 mg/day of ofloxacin. 12 of 14 patients with urinary tract infection and 4 of 8 patients with respiratory tract infection was cured and clinically improved. 12 of 13 E. coli isolates were eradicated with this treatment. No severe adverse reactions were observed. No in vitro resistance against ofloxacin was seen.
Hasçelik
G
G
Hacettepe Universitesi, Tip Fakültesi, Mikrobiyoloji Anabilim Dali Oğretim Görevlisi.
D000208:Acute Disease; D002908:Chronic Disease; D004926:Escherichia coli / Q000187:drug effects; D006801:Humans; D007709:Klebsiella / Q000187:drug effects; D015242:Ofloxacin / Q000494:pharmacology / Q000627:therapeutic use*; D011511:Proteus / Q000187:drug effects; D011549:Pseudomonas / Q000187:drug effects; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D014552:Urinary Tract Infections / Q000188:drug therapy*
D015242:Ofloxacin
Idrar ve solunum yolu enfeksiyonlarinda ofloxacin (tarivid) tedavisinin rolü.